General
All the material were purchased from commercial suppliers and used without further purification. All of the solvents were reagent grade and, when necessary, were purified and dried using standard methods. Flash chromatography was performed using silica gel (200-300 mesh). Reactions were monitored by thin layer chromatography on 0.25 mm silica gel plates (60GF-254) and visualized with UV light. The melting points were determined on an electrothermal melting point apparatus and uncorrected. The 1 H NMR and 13 C NMR spectra were determined on a Bruker ARX-400 MHz spectrometer using TMS as an internal standard in or CDCl 3 solutions. Chemical shifts were reported in delta (d) units, parts per million (ppm) downfield from trimethylsilane. High-resolution mass spectra (HRMS) were determined on an Agilent G3250AA LC/MSD TOF mass spectrometer and reported as m/z (relative intensity). The single crystal X-ray diffraction was determined on a Rigaku RAXIS RAPID IP CCD area-detector diffractometer.
General procedure for the synthesis of 3a-3b
A mixture of picoline 1a-1b (100 mmol), 4-hydroxybenzaldehyde 2 (12.21 g, 100 mmol), acetic anhydride (20.42 g, 200 mmol) and acetic acid (1.20 g, 20 mmol) in a round bottomed flask equipped with an anhydrous CaCl 2 drying tube was heated under reflux for 24 h. Volatile solvent was distilled out and the reaction residue was cooled. The residue was dissolved in CH 2 Cl 2 (80 mL), washed with 20% NaHCO 3 aqueous solution (80 mL) and distilled water (50 mL×2), respectively. The separated organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated by a rotary evaporator. The crude product was dissolved in hot EtOH and crystallized to afford 3a-3b. 4H), 7.38 (d, J = 7.4 Hz, 1H), 4H) , 2.32 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 169. 36, 155.42, 150.60, 149.66, 136.57, 134.45, 131.67, 128.11, 128.07, 122.18, 122.13, 121.87, 21.15 57, 151.08, 150.49, 144.63, 134.31, 132.49, 128.56, 126.54, 122.72, 121.31, 21.33 
4-(2-(2-Pyridinyl)ethenyl)phenyl acetate (3a)
O
4-(2-(4-Pyridinyl)ethenyl)phenyl acetate (3b)
General procedure for the synthesis of 4a-4b
To a solution of 3a-3b (11.95 g, 50 mmol) in ethanol (80 mL) was added a 2M KOH aqueous solution (12 mL). The mixture was refluxed for 12 h. To the solution was added 1M HCl solution to acidify to pH 5-6. The precipitate was filtered off and recrystallized from ethanol to obtain 4a-4b.
4-(2-(2-Pyridinyl)ethenyl)phenol (4a)
HO N White solid (yield 92%), mp: 217.0-217.7 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.73 (s, 1H), 8.53 (d, J = 4.5 Hz, 1H), 1H), 7.58 (d, J = 16.1 Hz, 1H), 3H), 1H), 7.08 (d, J = 16.1 Hz, 1H), 6.80 (d, J = 8.3 Hz, 2H); 13 C NMR (100 MHz, DMSO-d 6 ) δ 158. 41, 155.95, 149.81, 137.13, 132.56, 129.04, S4 127.86, 125.19, 122.25, 122.19, 116.10; HRMS (ESI) 68, 150.34, 145.26, 133.51, 129.12, 127.65, 122.91, 120.94, 116.14 
4-Chloropicolinoyl chloride (6)
Anhydrous DMF (0.1 mL) was added to thionyl chloride (100 mL) at 50 ºC under nitrogen. The solution was stirred at 50 ºC for 10 min prior to portionwise addition of picolinic acid 5 (36.93 g, 300 mmol) over 30 min. The solution was heated to reflux for 17 h. The mixture was then cooled to room temperature, diluted with toluene (100 mL), and concentrated under reduced pressure. This process was repeated two additional times to afford 6 as a brown oil that was used in the next step without further purification.
General procedure for the synthesis of 7a-7k
4-Chloropicolinoyl chloride 6 (1.75 g, 10 mmol) was dissolved in dichloromethane (15 mL) and this solution was added dropwise over 30 min to a solution of amine (12 mmol) in dichloromethane (15 mL) held at 0 ºC. After completion of the addition, the reaction mixture was allowed to warm to room temperature and stirring was continued for a further 3 h. The solution was washed with brine (40 mL×2) and the organic layer was dried over anhydrous Na 2 SO 4 , filtered and evaporated under reduced pressure. The residue was purified by chromatography (ethyl acetate/petroleum ether) on silica gel to afford 7a-7k. (dd, J = 5.2, 2.0 Hz, 1H), 7.42 (t, J = 7.9 Hz, 2H), 7.19 (t, J = 7.4 Hz, 1H); 13 C NMR (100 MHz, CDCl 3 ) δ 160. 73, 151.31, 148.82, 146.32, 137.42, 129.14, 126.63, 124.61, 123.09, 119.74; HRMS (ESI) CDCl 3 ) δ 160. 48, 156.60, 151.52, 148.80, 146.22, 130.69, 126.44, 122.95, 121.30, 114.30, 55.50 93, 159.08, 151.36, 148.95, 145.85, 130.03, 129.22, 126.30, 122.96, 114.11, 55.29, 43.09 163.07, 151.22, 148.98, 145.97, 133.47, 129.55, 129.47, 126.42, 123.04, 115.69, 115.47, 42.89 151.66, 148.82, 145.81, 126.11, 122.78, 41.54, 22.70 ; HRMS (ESI) m/z: calcd for 04, 151.75, 148.82, 145.80, 126.08, 122.82, 48.30, 32.98, 25.55, 24.81 
4-Chloro-N-methylpicolinamide (7a)

4-Chloro-N-(4-methoxybenzyl)picolinamide (7f)
N
4-Chloro-N-isopropylpicolinamide (7h)
General procedure for the synthesis of 8a-8v
A mixture of 4a-4b (1 mmol) and 7a-7k (1 mmol) were suspended in DMF (5 ml), then copper powder (6.4 mg, 0.1 mmol) and cesium carbonate (815 mg, 2.5 mmol) were added. The reaction mixture was held at 110 ºC under nitrogen for 6 h, and then diluted with ethyl acetate (30 ml). The organic layer was washed with brine (25 mL×3), dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by chromatography (ethyl acetate/petroleum ether) on silica gel to afford 8a-8v. 96, 164.47, 155.33, 153.78, 152.37, 149.75, 149.64, 136.63, 134.30, 131.47, 128.93, 128.19, 122.25, 122.20, 120.99, 114.34, 110.52, 26.13 153. 64, 152.22, 149.68, 149.67, 137.67, 136.65, 134.49, 131.42, 129.08, 129.00, 128.31, 124.35, 122.28, 122.24, 121.09, 119.62, 114.67, 110.65 N-(4-Methoxyphenyl)-4-(4-(2-(2-pyridinyl) 161.22, 156.40, 155.31, 153.70, 152.39, 149.62, 136.67, 134.43, 131.49, 130.97, 130.90, 128.98, 128.83, 128.24, 122.25, 121.14, 121.06, 114.53, 114.23, 110.57, 55.47 37, 161.53, 155.32, 153.60, 151.91, 149.67, 136.64, 136.27, 134.56, 131.42, 130.88, 129.29, 129.09, 129.00, 128.83, 128.36, 122.24, 121.06, 120.82, 114.78, 110.70 99, 163.80, 155.34, 153.73, 152.23, 149.81, 149.67, 138.16, 136.61, 134.36, 131.43, 128.95, 128.68, 128.27, 127.83, 127.46, 122.25, 122.20, 121.02, 114.51, 110.69, 43.55 94, 163.68, 158.99, 155.31, 153.72, 152.30, 149.79, 149.63, 136.60, 134.32, 131.42, 130.27, 129.19, 128.93, 128.24, 122.24, 122.19, 120.99, 114.45 162.87, 155.37, 153.78, 152.63, 149.68, 149.64, 136.54, 134.31, 131.42, 128.90, 128.25, 122.20, 122.15, 120.97, 114.32, 110.50, 41.43, 22.70 79, 162.54, 155.32, 153.75, 153.01, 150.82, 149.93, 137.20, 134.57, 131.33, 129.53, 128.87, 122.87, 122.84, 121.51, 114.92, 109.88, 48.44, 32.58, 25.52, 25.17 Hz, 1H), 7.33-7.18 (m, 5H), 7.08 (dd, J = 5.7, 2.5 Hz, 1H), 3.59 (t, J = 6.6 Hz, 2H), 3.47 (t, J = 6.6 Hz, 2H), 1.81 (m, 4H); 13 C NMR (100 MHz, DMSO-d 6 ) δ 165. 34, 165.12, 156.93, 155.32, 153.73, 150.68, 149.95, 137.27, 134.52, 131.34, 129.55, 128.84, 122.90, 121.59, 113.63, 111.43, 48.91, 46.88, 26.49, 23.93 72, 164.18, 153.97, 153.02, 150.99, 150.49, 144.63, 134.39, 132.36, 129.64, 126.79, 121.68, 121.40, 114.93, 109.71, 26.48 21, 161.46, 153.98, 152.27, 150.18, 149.70, 144.43, 137.64, 133.95, 131.88, 129.09, 128.96, 126.49, 124.39, 121.21, 120.90, 119.61, 114.83, 110.49; HRMS (ESI) 161.86, 159.93, 156.25, 153.95, 153.00, 150.98, 150.46, 134.48, 132.35, 131.78, 129.67, 126.87, 122.23, 121.71, 115.41, 115.31, 114.28, 110.18, 55.66 N-(4-Chlorophenyl)-4-(4-(2-(4-pyridinyl) 25, 161.49, 153.94, 151.97, 150.11, 149.72, 144.43, 136.24, 134.02, 131.87, 129.35, 129.11, 128.96, 128.83, 126.55, 121.18, 120.81, 114.93, 110.55 91, 163.74, 154.10, 152.29, 150.19, 149.83, 144.42, 138.11, 133.84, 131.90, 128.91, 128.69, 127.84, 127.49, 126.43, 121.14, 120.86, 114.67, 110.56, 43.58 86, 163.63, 159.02, 154.08, 152.34, 150.15, 149.82, 144.43, 133.79, 131.90, 130.23, 129.20, 128.91, 126.37, 121.12, 120.88, 114.62, 114.08, 110.51, 55.28, 43.04 94, 163.77, 163.41, 154.04, 152.15, 150.18, 149.85, 144.42, 133.97, 133.93, 133.86, 131.88, 129.55, 129.46, 128.92, 126.44, 121.15, 120.88, 115.62, 115.41, 114.73, 110.54, 42.84 85, 162.82, 154.12, 152.68, 150.16, 149.68, 144.28, 133.78, 131.83, 128.86, 126.42, 121.08, 114.48, 110.36, 41.45, 22.69; HRMS (ESI) 81, 165.08, 154.07, 152.30, 149.71, 149.44, 143.94, 133.84, 131.72, 128.83, 126.60, 121.07, 114.57, 110.29, 23.39, 6.29; HRMS (ESI) 8.52 (m, 3H), 8.42 (d, J = 8.5 Hz, 1H), 7.77 (d, J = 7.4 Hz, 2H), 3H), 7.47 (d, J = 2.5 Hz, 1H), 4H), 1H) , 1.79-1.53 (m, 5H), 1.42-1.09 (m, 5H); 13 C NMR (100 MHz, DMSO-d 6 ) δ 165. 74, 162.53, 154.00, 153.03, 150.86, 150.46, 144.62, 134.33, 132.32, 129.59, 126.75, 121.54, 121.31, S18 115.01, 109.90, 48.44, 32.57, 25.52, 25.17; HRMS (ESI) 36, 165.08, 156.95, 153.99, 150.73, 150.48, 144.66, 134.30, 132.38, 129.61, 126.72, 121.62, 121.34, 113.70, 111.45, 48.91, 46.87, 26.48, 23.94 
N-Methyl-4-(4-(2-(2-pyridinyl)ethenyl)phenoxy)picolinamide (8a)
N-(4-Fluorobenzyl)-4-(4-(2-(2-pyridinyl)ethenyl)phenoxy)picolinamide (8g)
N-Isopropyl-4-(4-(2-(2-pyridinyl)ethenyl)phenoxy)picolinamide (8h)
N-Cyclopropyl-4-(4-(2-(2-pyridinyl)ethenyl)phenoxy)picolinamide (8i)
N-Cyclohexyl-4-(4-(2-(2-pyridinyl)ethenyl)phenoxy)picolinamide (8j)
4-(4-(2-(2-Pyridinyl)ethenyl)phenoxy)-2-(pyrrolidin-1-yl-carbonyl)pyridine (8k)
Crystal X-ray diffraction for 8b and 8l
Crystals of 8b and 8l suitable for X-ray diffraction analysis were obtained by the slow evaporation of an ethyl acetate/dichloromethane solution of 8b and 8l at room temperature. The single crystal X-ray diffraction measurements were conducted on a Rigaku Saturn CCD area-detector diffractometer at 113 K using graphite monochromated MoKα radiation (λ = 0.71073 Å) in the ω and φ scanning mode. An empirical absorption correction was applied using the ABSCOR program. All structures were solved by direct methods using the SHELXS program and refined by full matrix least-squares on F 2 using the SHELXL program. All of the hydrogen atoms were geometrically fixed using the riding model. The crystallographic data of 8b (CCDC number 1588889) and 8l (CCDC number 1588886) were given in Table 1 . 
Biological evaluation
The antiproliferative activity was tested by CCK assay on A549 and HepG2 cell lines. The cell lines were obtained from Chinese Center for Disease Control and Prevention (Beijing, China). Briefly, cells were plated in 96-well plates at a concentration of 5×10 3 cells/well, and then incubated for 24 h in an atmosphere of 5% CO 2 at 37 °C. Compounds were respectively dissolved in DMSO to make stock solutions at a concentration of 2.0 × 10 -3 mol/L, and then the cells were treated with the diluted stock solutions at various concentrations (50, 25, 12.5, 6.25, 3.125, 1.6525 and 0.78125 μM). After 48 h treatment, the old medium was discarded and washed by PBS, then 10% CCK-8 solution was added to each well and the cells were further incubated for 2 h at 37 °C and with 5% CO 2 . Absorbance values were determined by a microplate reader (PerkinElmer, USA) at 450 nm. The IC 50 values were calculated from a log plot of percent of control versus concentration.
The inhibitory activity of VEGFR-2 was measured by use of the ADP-Glo TM kinase assay. It measured inhibitory activity by quantitating the amount of ATP remaining in solution after a kinase reaction. The general procedure was as the S20 following: Kinase was incubated with substrate, ATP and variable concentrations of target compounds in a buffer containing 40 mM Tris, 10 mM MgCl 2 , 0.1 mg/mL BSA, 1 mM DTT in a 384-well plate. The kinase reaction was allowed to proceed at 30 ˚C for 1 h, and then cooled for 5 min at room temperature. ADP-Glo reagent was added to stop the reaction and consumed the remaining ADP for 40 min, followed by another 30 min incubation with kinase detection reagent. The luminescence signal was measured by a VICTOR multilabel plate reader (PerkinElmer, USA). The signal was correlated with the amount of ATP present in the reaction and was inversely correlated with the kinase activity. The IC 50 value was determined as the concentration causing half-maximal percent activity.
Molecular docking
Molecular docking was performed using AutoDock 4.2 that used the Lamarckian genetic algorithm (LGA) to explore the full range of ligand conformational flexibility with partial flexibility of the receptor. The crystal structure of VEGFR-2 in complex with Sorafenib (PDB code: 4ASD) was retrieved from the Brookhaven Protein Data Bank, and the crystal structure of VEGFR-2 was extracted from the PDB file.
AutoDock Tool was used to assign polar hydrogens and Gasteiger charges. AutoGrid 4 was used to create affinity grid maps for all atom types. The docked conformations were generated using the LGA and the rest of the parameters were set to their default values. The model analysis was performed using the Discovery Studio 2016.
